Biodesix (BDSX) to Release Quarterly Earnings on Wednesday

Biodesix (NASDAQ:BDSX) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $26.0260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.32. The firm had revenue of $25.55 million during the quarter, compared to analysts’ expectations of $23.12 million. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. On average, analysts expect Biodesix to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biodesix Price Performance

Shares of BDSX stock traded up $0.17 on Wednesday, hitting $21.20. 7,094 shares of the stock traded hands, compared to its average volume of 667,502. The company has a debt-to-equity ratio of 5.09, a current ratio of 2.82 and a quick ratio of 2.82. Biodesix has a 52 week low of $5.26 and a 52 week high of $24.92. The firm has a 50 day simple moving average of $18.56 and a two-hundred day simple moving average of $14.94. The firm has a market cap of $219.58 million, a price-to-earnings ratio of -5.22 and a beta of 0.53.

Institutional Trading of Biodesix

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Biodesix in the fourth quarter valued at $187,000. State Street Corp grew its holdings in shares of Biodesix by 15.6% in the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after purchasing an additional 2,400 shares in the last quarter. Millennium Management LLC bought a new stake in Biodesix in the third quarter worth $113,000. Finally, DRW Securities LLC bought a new stake in Biodesix in the fourth quarter worth $105,000. Institutional investors own 20.96% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on BDSX. Roth Capital initiated coverage on shares of Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 target price for the company. Canaccord Genuity Group boosted their price objective on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, HC Wainwright began coverage on Biodesix in a research note on Monday, June 15th. They issued a “buy” rating and a $26.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biodesix presently has an average rating of “Moderate Buy” and an average target price of $28.33.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.